Andrew Lawrence
Florey Institute of Neuroscience & Mental Health
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Andrew Lawrence as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:38 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03897062 · Suvorexant in the Management Comorbid Sleep Disorder and Alcohol DependenceThe Florey Institute of Neuroscience and Mental Health · terminated · Insomnia, Alcohol Use Disorder · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:38 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:38 UTC. The ranking covers the 200 most relevant of 45 PubMed records, and a shared surname and initials can bring in a namesake. All 45 on PubMed
- A study of performance on tests from the CANTAB battery sensitive to frontal lobe dysfunction in a large sample of normal volunteers: implications for theories of executive functioning and cognitive aging. Cambridge Neuropsychological Test Automated Battery.J Int Neuropsychol Soc · 1998463 citationsRCR 14.8
- 413 citationsRCR 12.0
- 223 citationsRCR 10.5
- Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial.Lancet Neurol · 2016219 citationsRCR 10.9
- 153 citationsRCR 10.1
- 148 citationsRCR 3.8
- 130 citationsRCR 10.8
- Individual differences in threat sensitivity predict serotonergic modulation of amygdala response to fearful faces.Psychopharmacology (Berl) · 2005121 citationsRCR 3.3
- Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease.Brain · 2013119 citationsRCR 4.6
- TLR4 genotype and environmental LPS mediate RSV bronchiolitis through Th2 polarization.J Clin Invest · 2015110 citationsRCR 3.7